Raymond James analyst Patrick O’Shaughnessy downgrades CME Group (NASDAQ:CME) from Outperform to Market Perform.
‘Maker Of Promising Alzheimer’s Drug Leqembi Expects Full FDA Approval This Summer, Expanded Medicare Coverage’ – CNBC
https://www.cnbc.com/2023/02/17/maker-of-promising-alzheimer-drug-leqembi-expects-fdas-full-approval-this-summer.html
Eisai is anticipating full FDA approval of its early Alzheimer’s treatment, Leqembi, as soon
